MC Form 4: Kenneth Shropshire records RSU issuances tied to prior awards
Rhea-AI Filing Summary
Moelis & Co (MC) director Kenneth Shropshire reported receipt of restricted stock units on 09/18/2025. The Form 4 shows three dividend-equivalent RSU issuances tied to prior grants: 2024 Annual RSUs, 2025 Annual RSUs, and 2025 Elective RSUs. The filing lists numeric values associated with each line: 17.64 (2024 Annual), 14.72 (2025 Annual), and 1.74 (2025 Elective), and reports the amount of securities beneficially owned following the transactions as 2,127.9, 1,775.72, and 209.74 respectively. Shropshire is identified as a director and the Form 4 was signed by an attorney-in-fact, Osamu Watanabe, on 09/19/2025.
Positive
- Director received dividend-equivalent RSUs tied to prior awards, increasing reported beneficial ownership
- Vesting linkage disclosed: the dividend-equivalent RSUs will vest concurrently with the underlying Annual and Elective RSUs
Negative
- None.
Insights
TL;DR: Routine director compensation in the form of dividend-equivalent RSUs was reported; no cash sale or open-market trades are disclosed.
The Form 4 documents issuance of dividend-equivalent restricted stock units to Director Kenneth Shropshire on 09/18/2025 tied to prior Annual and Elective RSU awards. The filing lists post-transaction beneficial ownership amounts for each RSU line. There are no disclosed dispositions, option exercises, or open-market purchases in this filing, and no cash amounts or aggregate transaction prices are specified beyond the numeric entries shown on each line. For investors, this appears to be a compensation-related reporting event rather than a liquidity or market-trading event.
TL;DR: This is a standard Section 16 disclosure of dividend-equivalent RSUs to a director; it documents increased beneficial ownership from compensation.
The report identifies Shropshire as a director and lists three separate RSU issuances described as dividend equivalents that will vest concurrently with the underlying awards. The filing was executed by an attorney-in-fact. The disclosure specifies the nature of the RSUs and the vesting linkage to underlying grants, indicating these are non-derivative, compensation-related equity awards rather than discretionary market transactions. No material governance concerns or departures are noted in this document alone.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | 2024 Annual Restricted Stock Units | 17.64 | $0.00 | -- |
| Grant/Award | 2025 Annual Restricted Stock Units | 14.72 | $0.00 | -- |
| Grant/Award | 2025 Elective Restricted Stock Units | 1.74 | $0.00 | -- |
Footnotes (1)
- Each Restricted Stock Unit (RSU) represents the right to receive one share of Class A Common Stock. 2024 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 1, 2024. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs. 2025 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 1, 2025. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs. 2025 Elective RSUs were issued as dividend equivalents on holder's underlying Elective RSUs issued on July 1, 2025. The dividend equivalent Elective RSUs will vest concurrently with the vesting of the underlying Elective RSUs.
